How do we define PPG? How do we confirm its presence as an actionable metabolic derangement in need of intervention? And where does iGlarLixi fit into this treatment algorithm for PPG?

How do we define PPG? How do we confirm its presence as an actionable metabolic derangement in need of intervention? And where does iGlarLixi fit into this treatment algorithm for PPG?

How do we define PPG? How do we confirm its presence as an actionable metabolic derangement in need of intervention? And where does iGlarLixi fit into this treatment algorithm for PPG?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lawrence Leiter, MD, FRCP(C), FACP

Lawrence Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism Director, Lipid Clinic Associate Director, Clinical Nutrition and Risk Factor Modification Centre St. Michael’s Hospital Professor of Medicine and Nutritional Sciences University of Toronto Toronto, Ontario